• Radiation Oncology Journal
• /
• 제6권1호
• /
• pp.13-22
• /
• 1988

This study is the retrospective evaluation of ninety-six patients with biopsy-proven carcinoma of nasopharynx treated with radiotherapy at Yonsei University, College of Medicine, Radiation Oncology from January 1971 to December 1985. Patient's age ranged from 15 to 71 years with a median age of 49 years. Fifty-two point five percent of local control and $47.5\%$ of actuarial 5 year survival were achieved with radical radiotherapy. Five year survival rate for Stage I&II, III and IV were $75.0\%,\;74.6\%\;and\;41.4\%$, respectively. Distant metastasis rate was related with N stage $(N1\;12.5\%,\;N1\;0\%,\;N2\;23.5\%,\;N3\;32.1\%$and histologic type (lymphoepithelioma $41.7\%$, squamous cell carcinoma $6.5\%$) but not with T stage. Thirty-one of sixty-seven patient covered adequate radiation field received induction chemotherapy. However induction chemotherapy does not appear to improve over all survival.

• Radiation Oncology Journal
• /
• 제36권4호
• /
• pp.341-347
• /
• 2018

Surgical excision along with use of postoperative radiotherapy forms an integral management of sinonasal teratocarcinosarcoma (SNTCS). However, given the rarity of the tumor, no standardised guidelines, dose, technique and target delineation exist especially in the era of modern radiation delivery techniques. This is a case of 55-year-old male diagnosed as SNTCS treated with radical ethmoidectomy followed by volumetric modulated radiotherapy, showing good local control and acceptable toxicity profile.

• Radiation Oncology Journal
• /
• 제33권2호
• /
• pp.109-116
• /
• 2015

Purpose: To analyze prognostic factors for locoregional recurrence (LRR), distant metastasis (DM), and overall survival (OS) in cervical cancer patients who underwent radical hysterectomy followed by postoperative radiotherapy (PORT) in a single institute. Materials and Methods: Clinicopathologic data of 135 patients with clinical stage IA2 to IIA2 cervical cancer treated with PORT from 2001 to 2012 were reviewed, retrospectively. Postoperative parametrial resection margin (PRM) and vaginal resection margin (VRM) were investigated separately. The median treatment dosage of external beam radiotherapy (EBRT) to the whole pelvis was 50.4 Gy in 1.8 Gy/fraction. High-dose-rate vaginal brachytherapy after EBRT was given to patients with positive or close VRMs. Concurrent platinum-based chemoradiotherapy (CCRT) was administered to 73 patients with positive resection margin, lymph node (LN) metastasis, or direct extension of parametrium. Kaplan-Meier method and log-rank test were used for analyzing LRR, DM, and OS; Cox regression was applied to analyze prognostic factors. Results: The 5-year disease-free survival was 79% and 5-year OS was 91%. In univariate analysis, positive or close PRM, LN metastasis, direct extension of parametrium, lymphovascular invasion, histology of adenocarcinoma, and chemotherapy were related with more DM and poor OS. In multivariate analysis, PRM and LN metastasis remained independent prognostic factors for OS. Conclusion: PORT after radical hysterectomy in uterine cervical cancer showed excellent OS in this study. Positive or close PRM after radical hysterectomy in uterine cervical cancer correlates with poor prognosis even with CCRT. Therefore, additional treatments to improve local control such as radiation boosting need to be considered.

• 대한후두음성언어의학회지
• /
• 제22권2호
• /
• pp.159-161
• /
• 2011

Malignant fibrous histiocytoma is one of the rare types of larynx tumor. The most common sites of the tumor are limbs, trunk, and retroperitoneal space, but tumor localization within head and neck are very rare. It is built of histiocytes, fibroblasts and multinuclear giant cells. A diagnosis of the tumor includes microscopic and immunohistologic examination with identification of specific tissue markers and intermediate filaments of proteins. This disease has been treated by several methods combining radical surgery, radiotherapy, and chemotherapy, but the prognosis is poor. We present 74-year-old Asian man with dysphonia for 2 years. The tumor of the larynx was examined on laryngoscopy. The radical surgery rendered the final pathological diagnosis, confirmed histologically and immunohistochemically as malignant fibrous histiocytoma. This tumor was treated with laser cordectomy followed by radiotherapy. 3.5 year's observation of the patient didn't either show any signs of recurrence or dysphonia.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권9호
• /
• pp.3741-3745
• /
• 2015

Background: A moderate dose of radiation is the recommended treatment for solitary plasmacytoma (SP), but there is controversy over the role of surgery. Our study aimed at comparing different treatment modalities in the management of SP. Materials and Methods: Data from 38 consecutive patients with solitary plasmacytoma, including 16 with bone plasmacytoma and 22 with extramedullary plasmacytoma, were retrospectively reviewed. 15 patients received radiotherapy alone; 11 received surgery alone, and 12 received both. The median radiation dose was 50Gy. All operations were performed as radical resections. Local progression-free survival (LPFS), multiple myeloma-free survival (MMFS), progression-free survival (PFS) and overall survival (OS) were calculated and outcomes of different therapies were compared. Results: The median follow-up time was 55 months. 5-year LPFS, MMFS, PFS and OS were 87.0%, 80.9%, 69.8% and 87.4%, respectively. Univariate analysis revealed, compared with surgery alone, radiotherapy alone was associated with significantly higher 5-year LPFS (100% vs 69.3%, p=0.016), MMFS (100% vs 51.4%, p=0.006), PFS (100% vs 33.7%, p=0.0004) and OS (100% vs 70%, p=0.041). Conclusions: Radiotherapy alone can be considered as a more effective treatment for SP over surgery. Whether a combination of radiotherapy and surgery improves outcomes requires further study.

• Radiation Oncology Journal
• /
• 제33권1호
• /
• pp.29-35
• /
• 2015

Purpose: To analyze the prognostic factors for survivals and to evaluate the impact of postoperative whole pelvic radiotherapy (WPRT) on pelvic failure in patients with uterine sarcoma treated with radical surgery. Materials and Methods: We retrospectively analyzed 75 patients with uterine sarcoma who underwent radical surgery with (n = 22) or without (n = 53) radiotherapy between 1990 and 2010. There were 23 and 52 patients with carcinosarcoma and non-carcinosarcoma (leiomyosarcoma, 22; endometrial stromal sarcoma, 25; others, 5), respectively. The median follow-up period was 64 months (range, 17 to 269 months). Results: The 5-year overall survival (OS) and pelvic failure-free survival (PFFS) of total patients was 64.2% and 83.4%, respectively. Multivariate analysis revealed that mitotic count (p = 0.006) was a significant predictor of OS. However, factors were not found to be associated with PFFS. On analyzing each of the histologic subtypes separately, postoperative WPRT significantly reduced pelvic failure in patients with carcinosarcoma (10.0% vs. 53.7%; p = 0.046), but not in patients with non-carcinosarcoma (12.5% vs. 9.9%; p = 0.866). Among the patients with carcinosarcoma, 4 patients (17%) had recurrence within the pelvis and 3 patients (13%) had recurrence in other sites as an initial failure, whereas among the patients with non-carcinosarcoma, 3 patients (6%) experienced pelvic failure and 13 patients (25%) experienced distant failure. Conclusion: The most significant predictor of OS was mitotic count. Based on the improved PFFS after postoperative WPRT only in patients with carcinosarcoma and the difference in patterns of failure between histologic subtypes, optimal adjuvant treatment options should be offered to patients based on the risk of recurrence patterns.

• Radiation Oncology Journal
• /
• 제19권3호
• /
• pp.237-244
• /
• 2001

목적 : 침윤성 방광암 환자를 대상으로 TURBT (Transurethral Resection of Bladder Tumor)과 유도 항암화학요법(neoadjuvant MCV chemotherapy) 후 방사선 항암화학 병용요법(cisplatin chemotherapy and radiotherapy)을 받은 환자에서 치료의 적응도, 국소 반응율, 방광 보존율과 생존율을 알아보고자 하였다. 대상 및 방법 : 1990년 10월부터 1998년 6월까지 TURBT 시행 후 병리 조직검사 상 침윤성 방광 이행상피암으로 진단 받은 병기 T2-T4, Grade II 환자 21명을 대상으로 하였다. 치료과정은 TURBT 후 4주 간격으로 2회의 유도 MCV(methotrexate, cisplatin, vinblastine) 복합 항암화학요법을 시행하고 그 후 cisplatin과 방사선 동시 병용요법을 시행하였다. 방사선치료는 $6\~15$ MV X-ray를 사용하여 하루 1.8 Gy씩 $39.6\~45\;Gy$를 전 골반에 $4\~5$주간에 걸쳐 조사하였다. 치료 종료 후 방광내시경을 통해 관해율을 판정하여 완전 관해인 경우 $1\~2$주 후 보강 방사선조사를 cisplatin과 병용하여 19.8 Gy를 시행하였다. 부분 관해인 경우 근치적 방광 절제술을 예정하였고 수술이 불가능한 경우에는 항암제 병용 강화 방사선치료를 받도록 하였다. 환자의 추적관찰기간은 $34\~67$개월로 중앙값이 49.5개월이었다. 결과 : 총 26명의 환자가 유도 항암화학요법을 위해 등록되었으며 유도 항암화학요법과 방사선 항암화학 병용요법을 완료한 환자는 21명$(81\%)$이었다. 유도 항암화학요법과 방사선 항암화학 병용요법 후 방광내시경을 통해 완전 관해 판정을 받은 환자는 21명 중 7명$(33\%)$이었고 부분 관해 환자는 14명$(67\%)$이었다. 완전 관해 환자 중 강화 항암제 병용 방사선 19.8 Gy를 받은 환자는 7명 중 6명$(85\%)$이었고, 이들 중 5명$(14\%)$은 재발 없이 방광을 보존하였다. 부분관해 환자중 1명이 근치적 방광적출술을 받았으며 3명이 TURBT와 2회의 MCV 항암요법을, 10명이 추가의 항암화학 방사선 병용요법을 받았다. 근치적 방광적출술을 받은 1명은 수술 소견상 방광 내 종양이 존재했으나 수술 후 재발이 없었다. 전체 21명의 환자중 12명$(58\%)$이 방광을 보존하면서 생존하고 있고 8명이 방광암으로 사망하였으며 1명이 다른 질병으로 사망하였다. 전체 환자의 중앙 생존기간은 27개월이며, 5년 생존율은 $55\%$ 였다. 유도 항암화학요법과 항암제 방사선치료 후 완전 관해 환자의 경우 5년 생존율은 $80\%$, 부분 관해 환자 $14\%$로 의미 있는 차이를 보였다(p=0.001). 유도 항암화학요법과 항암제 병용 방사선치료를 받은 환자에서 grade 3 이상의 혈액학적 부작용의 빈도는 각각 백혈구 감소증 6명$(29\%)$, 혈소판 감소증 1명$(4\%)$이었으며 이로 인한 화학요법의 지연은 1명$(4\%)$에서 관찰되었다. 결론 : 침윤성 방광암 환자에서 유도 항암화학요법 및 항암제 병용 방사선치료를 적용하여 방광 보존을 및 5년 생존율에 있어 만족할 만한 결과를 얻었다. 완전한 TURBT와 유도 MCV 항암요법과 cisplatin 방사선 병용요법에서 완전관해 여부가 방광보존가능성과 생존율에 영향을 미치는 요소로 생각되고 만약 완전관해를 이루지 못하면 근치적 방광적출술을 시행하는 것이 바람직할 것이다.

• Radiation Oncology Journal
• /
• 제6권2호
• /
• pp.283-288
• /
• 1988

초기 유방암의 치료는 근치적 절제술이 오랫동안 주된 치료방법으로써 선택되어 왔으나, 근래에는 여성의 유방을 보존하고 미용효과를 기대할 수 있는 보조적 절제술 후 근치적 방사선치료법이 개발되어 지대한 관심과 상당한 논란이 거듭되어 왔다. 이러한 논란을 해결하기 위하여 그동안 세계적으로 많은 후향성 또는 전향성 분석을 시행하여 두 치료방법사이의 치료효과를 비교하여 본 결과, 국소치료율, 재발을, 그리고 생존율에 있어서 큰 차이를 보이지 않았다. 이와 같은 치료성적의 결과를 토대로 하여 최근에는 보조적 절제술 후 근치적 방사선치료법이 여성들의 유방을 보존하고 미용효과를 향상시킬 수 있을 뿐만 아니라 국소치료율, 재발율, 생존율도 근치적 절제술의 성적과 대동소이하므로 초기 유방암의 치료에 활발히 이용되기에 이르렀다. 본원에서도 이러한 추세에 따라서 보조적 절제술 후 근치적 방사선치료를 시행한 초기 유방암 1예를 보고하면서 아울러 많은 문헌고찰과 함께 향후 치료방침을 세우고자 한다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권10호
• /
• pp.5237-5240
• /
• 2012

Objective: This observational study was to identify risk factors for vulvar cancer recurrence. Materials and Methods: In the study 107 patients with primary vulvar cancer were analyzed. Surgical treatment consisted of radical excision of the primary tumor in combination with unilateral or bilateral superficial and deep inguinofemoral lymphadenectomy through separate incisions. Patients with deeper tumor invasion >1 mm or wider than 2 cm and/or groin lymphnode metastases were referred for adjuvant radiotherapy. Those with large privary vulvar tumors received neoadjuvant radiotherapy of 30Gy followed by surgical treatment and adjuvant radiotherapy. Results: Most of patients had only primary radiotherapy to the vulva and inguinal lymph nodes and only 34.5% of patients were eligible for surgical treatment. In 5 year follow-up period 25.2% (27) patients were alive without the disease, 15.0% (16) were alive with the disease and 59.8% (64) were dead. 60.7% (65) patients experienced local recurrence and 2.8% (3) patients had distant metastases. Median survival for patients without recurrent disease was $38.9{\pm}3.2$ months and $36.0{\pm}2.6$ months with no statistically significant difference. Patients with early stage vulvar cancer had longer mean survival rates-for stage I $53.1{\pm}3.4$ months, $38.4{\pm}4.4$ months for stage II and $33.4{\pm}2.6$ and $15.6{\pm}5.2$ months for patients with stage III and stage IV vulvar cancer, respectively. The only signifficant prognostic factor predicting vulvar cancer recurrence was involvement of the midline. Conclusions: Patients having midline involvement of vulvar cancer has lower recurrence risk, probably because of receiving more aggressive treatment. There is a tendency for lower vulvar cancer recurrence risk for patients over 70 years of age and patients who are receiving radiotherapy as an only treatment without surgery, but tendency for higher risk of recurrence in patients with multifocal vulvar cancer.

• Radiation Oncology Journal
• /
• 제36권1호
• /
• pp.71-78
• /
• 2018

Purpose: To compare the dose distribution of three-dimensional conformal radiation therapy (3DCRT) with intensity-modulated radiation therapy (IMRT) for post-mastectomy radiotherapy (PMRT) to left chest wall. Materials and Methods: One hundred and seven patients were randomised for PMRT in 3DCRT group (n = 64) and IMRT group (n = 43). All patients received 50 Gy in 25 fractions. Planning target volume (PTV) parameters-$D_{near-max}$ ($D_2$), $D_{near-min}$ ($D_{98}$), $D_{mean}$, $V_{95}$, and $V_{107}$-homogeneity index (HI), and conformity index (CI) were compared. The mean doses of lung and heart, percentage volume of ipsilateral lung receiving 5 Gy ($V_5$), 20 Gy ($V_{20}$), and 55 Gy ($V_{55}$) and that of heart receiving 5 Gy ($V_5$), 25 Gy ($V_{25}$), and 45 Gy ($V_{45}$) were extracted from dose-volume histograms and compared. Results: PTV parameters were comparable between the two groups. CI was significantly improved with IMRT (1.127 vs. 1.254, p < 0.001) but HI was similar (0.094 vs. 0.096, p = 0.83) compared to 3DCRT. IMRT in comparison to 3DCRT significantly reduced the high-dose volumes of lung ($V_{20}$, 22.09% vs. 30.16%; $V_{55}$, 5.16% vs. 10.27%; p < 0.001) and heart ($V_{25}$, 4.59% vs. 9.19%; $V_{45}$, 1.85% vs. 7.09%; p < 0.001); mean dose of lung and heart (11.39 vs. 14.22 Gy and 4.57 vs. 8.96 Gy, respectively; p < 0.001) but not the low-dose volume ($V_5$ lung, 61.48% vs. 51.05%; $V_5$ heart, 31.02% vs. 23.27%; p < 0.001). Conclusions: For left sided breast cancer, IMRT significantly improves the conformity of plan and reduce the mean dose and high-dose volumes of ipsilateral lung and heart compared to 3DCRT, but 3DCRT is superior in terms of low-dose volume.